Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

The lentiviral-mediated Nurr1 genetic engineering mesenchymal stem cells protect dopaminergic neurons in a rat model of Parkinson's disease.

American journal of translational research | 2018

Nuclear receptor-related factor 1 (Nurr1) has a crucial role in the development and maturation of mesencephalic dopamine (DA) neurons and also plays a protective role in maintenance of DA neurons by inhibiting the activation of microglia and astrocyte. Moreover, the mutations in Nurr1 gene are associated with familial Parkinson's disease (PD), suggested that Nurr1 modulation is a potential therapeutic target for PD. This study examines the therapeutic effects of transplantation of Nurr1 gene-modified bone marrow mesenchymal stem cells (MSCs) on 6-hydroxydopamine (6-OHDA)-induced PD rat models. MSCs were transduced with lentivirus expressing Nurr1 gene and then intrastriatally transplanted into PD rats. Our results showed that Nurr1 gene-modified MSCs overexpress and secrete Nurr1 protein in vitro and also survive and migrate in the brain. Four weeks after transplantation Nurr1 gene-modified MSCs dramatically ameliorated the abnormal behavior of PD rats and increased the numbers of tyrosine hydroxylase (TH)-positive cells in the substantia nigra (SN) and TH-positive fibers in the striatum, inhibited the activation of glial cells, and reduced the expression of inflammatory factors in the SN. Taken together, these findings suggest that intrastriatal transplantation of lentiviral vector mediated Nurr1 gene-modified MSCs has notable therapeutic effect for PD rats.

Pubmed ID: 30018702 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


DAT (H-80) (antibody)

RRID:AB_2190287

This polyclonal targets SLC6A3

View all literature mentions

Nurr1 antibody (antibody)

RRID:AB_10563537

This polyclonal targets Nurr1 antibody

View all literature mentions

Anti-Integrin alphaM [CD11b], clone OX-42 (antibody)

RRID:AB_93253

This monoclonal targets Integrin alphaM [CD11b] clone OX-42

View all literature mentions

GFAP (H-50) (antibody)

RRID:AB_641022

This polyclonal targets GFAP

View all literature mentions

TNFalpha (N-19) (antibody)

RRID:AB_2204365

This polyclonal targets TNF

View all literature mentions

beta-Actin (AC-15) (antibody)

RRID:AB_1119529

This monoclonal targets beta-Actin (AC-15)

View all literature mentions

Cox-2 (N-20) (antibody)

RRID:AB_631310

This polyclonal targets Cox-2 (N-20)

View all literature mentions